Lab Reference Library / Plasma Tryptophan
Gut & Immune
Plasma Tryptophan
Plasma Tryptophan · Tryptophan / Kynurenine RatioReference range, optimal plasma tryptophan levels, and why tryptophan is the sole precursor for serotonin and melatonin production, how gut inflammation diverts tryptophan away from serotonin toward the kynurenine inflammatory pathway, and why tryptophan status is central to the gut-brain axis and mood.
Neurotransmitter PrecursorGut-Brain Axis
Standard Range45 to 74 µmol/L
FM Optimal55 to 74 µmol/L
Kynurenine RatioBelow 40
Unitsµmol/L
← Back to Lab Reference Library
Category: Gut & Immune | Also known as: Plasma Tryptophan, Serum Tryptophan, Trp, Serotonin Precursor Amino Acid
1. What This Test Measures
Plasma tryptophan measures the circulating concentration of tryptophan, the least abundant essential amino acid in the human diet and among the most biologically consequential. Tryptophan must be obtained entirely from dietary protein; the body cannot synthesize it de novo. Once absorbed, tryptophan does not serve a single dedicated pathway. It is the molecular hub of at least three major and competing metabolic pathways, each with profound consequences for mood, immunity, gut health, energy metabolism, and longevity: the serotonin pathway producing the mood and gut regulatory neurotransmitter serotonin and the sleep hormone melatonin; the kynurenine pathway producing NAD+ precursors but also the neurotoxic metabolite quinolinic acid when inflammation dominates; and the indole pathway through gut bacteria producing indole compounds that regulate intestinal barrier integrity and immune tolerance through aryl hydrocarbon receptor (AhR) signaling.
The clinical importance of plasma tryptophan extends well beyond its role as a serotonin precursor. In functional medicine, tryptophan is a sentinel marker for the intersection of systemic inflammation, gut health, mood regulation, and cellular energy: low plasma tryptophan in the context of elevated inflammatory markers signals that inflammation is actively diverting tryptophan away from serotonin production toward the kynurenine pathway, producing both a neurotransmitter deficit and a neuroexcitatory quinolinic acid excess simultaneously. Understanding which tryptophan pathway is being driven by the patient's current inflammatory and microbial environment determines whether the clinical target is inflammation reduction, gut dysbiosis treatment, dietary protein optimization, or B6 and cofactor support.
Plasma tryptophan is collected as a fasting morning specimen alongside the kynurenine-to-tryptophan ratio (KTR) for the most informative clinical picture. An elevated KTR with low tryptophan confirms active IDO1-mediated tryptophan diversion away from serotonin toward kynurenine, the inflammation-driven pattern. Normal KTR with low tryptophan suggests dietary insufficiency or malabsorption as the primary cause.
2. Optimal Range and Clinical Thresholds
| Plasma Tryptophan | Interpretation |
|---|---|
| Below 30 mcmol/L | Severely low: profound serotonin synthesis deficit; significant indole pathway depletion; urgent evaluation |
| 30 to 45 mcmol/L | Low: impaired serotonin, melatonin, and indole pathway capacity; evaluate inflammation, diet, malabsorption |
| 45 to 55 mcmol/L | Low-normal: below functional medicine optimal; symptomatic in sensitive individuals; support indicated |
| 55 to 75 mcmol/L | Optimal: adequate substrate for serotonin synthesis, melatonin production, and indole pathway function |
| Above 75 mcmol/L | High-normal: typically benign; evaluate for dietary excess or impaired kynurenine catabolism if persistent |
Tryptophan is transported across the blood-brain barrier by the large neutral amino acid (LNAA) transporter, competing with other LNAAs (leucine, isoleucine, valine, phenylalanine, tyrosine). The ratio of plasma tryptophan to competing LNAAs (tryptophan/LNAA ratio) better predicts brain tryptophan availability for serotonin synthesis than absolute plasma tryptophan alone. A high-carbohydrate meal increases brain tryptophan uptake by insulin-driven uptake of competing amino acids into muscle, which is the biochemical basis of the post-carbohydrate mood-calming effect observed in many individuals.
3. The Three Tryptophan Pathways and Their Relative Dominance
Serotonin and Melatonin Pathway
- Tryptophan to 5-hydroxytryptophan (5-HTP) via tryptophan hydroxylase (TPH); requires iron, oxygen, and tetrahydrobiopterin (BH4) as cofactors; this is the rate-limiting step in serotonin synthesis
- 5-HTP to serotonin (5-HT) via aromatic amino acid decarboxylase; requires pyridoxal-5-phosphate (active B6)
- Serotonin to melatonin via N-acetyltransferase and HIOMT in the pineal gland during darkness; magnesium and B6 support these reactions
- Approximately 90% of serotonin is produced in the gut (enterochromaffin cells); 10% in the brain; gut serotonin regulates intestinal motility, secretion, and pain signaling; cannot cross the blood-brain barrier; brain serotonin is synthesized locally from circulating tryptophan
- Pathway is strongly suppressed when IDO1 enzyme is activated by inflammatory cytokines; this is the primary mechanism linking systemic inflammation to serotonin deficiency and depression
- Under normal conditions, approximately 1 to 2% of dietary tryptophan enters the serotonin pathway; 95%+ enters the kynurenine pathway even in healthy, non-inflamed individuals
Kynurenine and Indole Pathways
- Kynurenine pathway: tryptophan converted to kynurenine by IDO1 (induced by IFN-gamma, LPS, and inflammatory cytokines) or TDO2 (hepatic, constitutively active); kynurenine branches to quinolinic acid (neurotoxic NMDA agonist) or kynurenic acid (neuroprotective NMDA antagonist) depending on downstream enzyme activity and B6/B3 cofactor availability
- Quinolinic acid excess: produced in activated microglia and macrophages during neuroinflammation; directly damages neurons through NMDA receptor overactivation; elevated in depression, Alzheimer disease, HIV encephalopathy, and chronic inflammatory conditions
- Kynurenine pathway also produces nicotinamide adenine dinucleotide (NAD+) via quinolinic acid phosphoribosyltransferase; the kynurenine pathway is the endogenous NAD+ synthesis route from tryptophan; chronic tryptophan deficiency contributes to NAD+ depletion in inflamed tissues
- Indole pathway: gut bacteria with tryptophanase enzyme (Lactobacillus, Clostridium sporogenes) convert tryptophan to indole and indole derivatives (indole-3-acetic acid, indole-3-propionic acid, indole-3-aldehyde); these indoles activate AhR receptors on intestinal epithelial cells and immune cells, maintaining barrier integrity and promoting IL-22 production; indole production is dramatically reduced by dysbiosis and antibiotic use
4. Why Inflammation Depletes Tryptophan and Serotonin
IDO1 (indoleamine 2,3-dioxygenase) is the enzyme that diverts tryptophan from the serotonin pathway into the kynurenine pathway. IDO1 is strongly and rapidly induced by interferon-gamma, TNF-alpha, LPS, and other inflammatory mediators as part of the acute-phase response. The evolutionary purpose of this diversion is believed to be starvation of intracellular pathogens of tryptophan (many bacteria and parasites require tryptophan for their own protein synthesis) and modulation of T cell activity through tryptophan depletion. The consequence in modern chronic inflammatory states is continuous tryptophan diversion producing simultaneously: depleted serotonin synthesis substrates, reduced melatonin, reduced indole pathway activity (worsening gut barrier integrity), excess quinolinic acid production (promoting neuroinflammation and excitotoxicity), and progressive tryptophan depletion in plasma.
The kynurenine-to-tryptophan ratio (KTR) quantifies the degree of IDO1 activation. A KTR above 25 to 30 nmol/mcmol indicates significant IDO1 upregulation and tryptophan catabolism through the inflammatory pathway. Elevated KTR with elevated hs-CRP, elevated IL-6, or clinical evidence of systemic inflammation confirms that inflammation is the primary driver of tryptophan depletion, and that treating the inflammation rather than supplementing tryptophan alone will produce the most durable improvement.
5. Causes of Low Plasma Tryptophan
- Chronic systemic inflammation with IDO1 activation: the most common cause of low tryptophan in functional medicine patients; IFN-gamma from any chronic immune activation (autoimmune disease, chronic infection, LPS from gut permeability, mold toxins, Lyme disease) upregulates IDO1 and accelerates tryptophan catabolism; the same inflammation producing fatigue, malaise, and joint pain is simultaneously depleting serotonin substrate through IDO1 activation
- Insufficient dietary protein intake: tryptophan is the least abundant amino acid in most proteins and is particularly sparse in plant proteins; low total protein intake, highly restrictive diets (very low calorie, very low protein), or inadequate dietary variety reduce the tryptophan pool; tryptophan requirements increase with inflammatory states further widening any dietary gap
- Gut dysbiosis and malabsorption: tryptophan is absorbed in the small intestine; SIBO, celiac disease, and inflammatory bowel disease reduce absorptive capacity; additionally, certain gut bacteria competitively consume dietary tryptophan for their own metabolic needs before it can be absorbed by the host enterocytes; dysbiosis that reduces AhR-stimulating indole production also reduces the indole pathway feedback that supports gut barrier function, creating a reinforcing dysbiosis-permeability cycle
- Vitamin B6 deficiency: B6 (as P5P) is required for the aromatic amino acid decarboxylase step converting 5-HTP to serotonin; B6 deficiency does not reduce plasma tryptophan directly but impairs its conversion to serotonin, producing functional serotonin deficiency despite potentially normal plasma tryptophan levels; plasma tryptophan low alongside elevated xanthurenate on OAT confirms concurrent B6 deficiency
- Chronic psychological stress: cortisol induces hepatic TDO2 (tryptophan dioxygenase, the non-inflammatory IDO1 homolog in the liver), diverting tryptophan to kynurenine through a stress-driven rather than inflammation-driven mechanism; chronic cortisol elevation produces tryptophan depletion through TDO2 induction even in the absence of elevated inflammatory markers
- Age-related increase in kynurenine pathway activity: IDO1 expression increases with aging as part of the inflammaging process; older adults show higher KTR ratios and lower tryptophan availability for serotonin synthesis, contributing to age-related sleep disruption, mood changes, and potentially neurodegenerative disease progression through excess quinolinic acid production
6. How to Optimize Plasma Tryptophan
Reduce IDO1 Activation
- Anti-inflammatory protocol targeting IDO1 drivers: the most impactful intervention for inflammation-driven tryptophan depletion is reducing the inflammatory signals activating IDO1; omega-3 fatty acids (2 to 4g EPA/DHA daily) reduce IFN-gamma and LPS-driven IDO1 induction; curcumin and resveratrol directly inhibit IDO1 enzyme activity at therapeutic concentrations; this approach addresses the upstream cause rather than supplementing downstream of the blockade
- Gut barrier restoration: reducing LPS translocation (a potent IDO1 inducer) through zonulin reduction, SIBO treatment, and gut barrier repair with L-glutamine and zinc carnosine reduces the chronic IDO1 activation from metabolic endotoxemia
- Treat chronic infections: H. pylori, Lyme, EBV, and other chronic infections continuously activate IFN-gamma and IDO1; eradication or management of these infections removes a primary IDO1 driver
- Stress reduction: reducing cortisol-driven TDO2 induction through HPA axis support, sleep optimization, and psychological stress management reduces the non-inflammatory hepatic tryptophan catabolism route
Increase Tryptophan Availability
- Dietary tryptophan optimization: the highest tryptophan foods per gram of protein are turkey, chicken, tuna, pumpkin seeds, sesame seeds, dairy products, eggs, and spirulina; a varied high-protein diet consuming 1.4 to 2.0g protein per kg body weight daily provides adequate tryptophan substrate; vegetarians and vegans need particular attention to tryptophan density of plant protein sources
- 5-HTP supplementation (50 to 300mg daily, taken separately from protein meals): 5-HTP bypasses the tryptophan hydroxylase rate-limiting step and IDO1 competition by entering the serotonin pathway downstream of both; effective for directly increasing serotonin synthesis but should be used cautiously alongside SSRIs or MAOIs; requires B6 (as P5P) for the final decarboxylase step
- Tryptophan supplementation (500 to 2,000mg daily, at bedtime): direct tryptophan supplementation increases plasma levels but must compete with other LNAAs for BBB transport; most effective taken alone at night without competing amino acids, with a small carbohydrate snack to drive competing amino acids into muscle; clinical evidence for sleep quality improvement and serotonin support
- Carbohydrate timing: consuming carbohydrates alongside tryptophan-rich protein sources strategically promotes brain tryptophan uptake by insulin-driven clearance of competing LNAAs from circulation
Support Pathway Cofactors
- Vitamin B6 (P5P form, 25 to 50mg daily): essential for the aromatic amino acid decarboxylase step converting 5-HTP to serotonin, for transaminase reactions in kynurenine metabolism, and for DAO activity managing histamine that is frequently co-elevated with low tryptophan; check for functional B6 deficiency with OAT xanthurenate before assuming adequacy from serum B6 alone
- Iron optimization: tryptophan hydroxylase (TPH) requires iron as a cofactor for the rate-limiting step of serotonin synthesis; iron deficiency can impair serotonin synthesis independent of tryptophan levels; optimize ferritin above 50 ng/mL for adequate TPH function
- Magnesium (glycinate or malate, 300 to 400mg daily): required for tryptophan hydroxylase activity and for downstream reactions in serotonin-melatonin conversion; magnesium deficiency is extremely common and impairs the entire serotonin synthesis pathway from tryptophan onward
- Restore indole-producing gut bacteria: prebiotic fiber (inulin, GOS), fermented foods containing Lactobacillus species with tryptophanase activity, and addressing dysbiosis that has reduced the commensal bacteria producing AhR-activating indoles from dietary tryptophan
7. Related Lab Tests
hs-CRPInflammation Activating IDO1 and Diverting Tryptophan to Kynurenine
→
Organic Acids Test5-HIAA, Quinolinate, and Kynurenate for Full Pathway Picture
→
Vitamin B6 (P5P)Required for Serotonin Synthesis from Tryptophan
→
FerritinIron Required for Tryptophan Hydroxylase Rate-Limiting Step
→
NAD+Kynurenine Pathway Is the Endogenous NAD+ Synthesis Route from Tryptophan
→
ZonulinGut Permeability Reduces Indole Pathway and Drives IDO1 via LPS
→
8. Clinical Perspective
Clinical Perspective
Plasma tryptophan alongside the kynurenine-to-tryptophan ratio is one of the most informative two-test combinations I use for patients presenting with depression, insomnia, anxiety, brain fog, and gut symptoms simultaneously, because it tells me immediately whether the serotonin deficit is dietary or inflammatory in origin. A patient with plasma tryptophan of 32 mcmol/L, KTR of 45, and hs-CRP of 6.2 does not have a serotonin problem. They have an inflammation problem that is consuming their tryptophan. Supplementing 5-HTP or tryptophan into that patient without addressing the IDO1 activation from the chronic inflammatory state will produce partial, temporary results at best. The tryptophan will continue to be diverted to kynurenine as fast as it is supplemented. Reduce the inflammation, heal the gut barrier that is driving LPS-mediated IDO1 induction, and the tryptophan normalizes, the serotonin pathways restore, and the mood and sleep improve as a downstream consequence of treating the actual problem upstream. The test does not just identify a deficiency. It identifies the mechanism, and the mechanism determines the treatment.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
9. Frequently Asked Questions
What is the optimal plasma tryptophan level?
In functional medicine, optimal plasma tryptophan is 55 to 75 mcmol/L, providing adequate substrate for serotonin synthesis, melatonin production, and indole pathway function. Values below 40 mcmol/L are associated with impaired serotonin synthesis, disrupted sleep through reduced melatonin, impaired gut barrier function through reduced indole AhR signaling, and when accompanied by elevated hs-CRP or elevated kynurenine-to-tryptophan ratio, confirm active IDO1-mediated tryptophan diversion by systemic inflammation.
Why does inflammation lower tryptophan?
The enzyme IDO1 (indoleamine 2,3-dioxygenase) is strongly upregulated by inflammatory cytokines, especially interferon-gamma. IDO1 diverts tryptophan from the serotonin pathway into the kynurenine pathway, depleting serotonin precursor supply while increasing production of kynurenine and potentially neurotoxic quinolinic acid. This inflammation-driven tryptophan depletion is the mechanistic link between chronic systemic inflammation and depression: the same immune activation producing fatigue and malaise also depletes the substrate required for serotonin and melatonin synthesis.
What are the three tryptophan pathways?
Tryptophan is metabolized through three competing pathways: the serotonin pathway (producing serotonin and melatonin; mood, sleep, and gut motility regulation), the kynurenine pathway (producing NAD+ precursors but also neurotoxic quinolinic acid when inflammation drives IDO1; 90 to 95% of tryptophan under inflammatory conditions), and the indole pathway through gut bacteria (producing AhR-activating indoles maintaining intestinal barrier integrity and immune tolerance). Chronic inflammation and dysbiosis simultaneously deplete the serotonin and indole pathways while driving excess quinolinic acid production.
What causes low plasma tryptophan?
Primary causes: chronic systemic inflammation activating IDO1 and accelerating tryptophan catabolism through the kynurenine pathway, insufficient dietary protein intake (tryptophan is an essential amino acid requiring dietary supply), gut dysbiosis and SIBO reducing tryptophan absorption and increasing bacterial tryptophan consumption, vitamin B6 deficiency impairing tryptophan hydroxylase activity, chronic psychological stress inducing hepatic TDO2 (the non-inflammatory tryptophan catabolism enzyme), and age-related increase in IDO1 expression as part of inflammaging.
How do you raise plasma tryptophan?
For inflammation-driven depletion: reduce IDO1 activators (omega-3 fatty acids, curcumin, and resveratrol inhibit IDO1; gut barrier restoration reduces LPS-driven IDO1 induction; treat underlying chronic infections). For dietary depletion: increase tryptophan-rich foods (turkey, seeds, tuna, eggs, dairy), ensure 1.4 to 2.0g total protein per kg body weight daily. Supplementation: 5-HTP (50 to 300mg daily bypasses IDO1 competition) or tryptophan (500 to 2,000mg at bedtime with small carbohydrate snack). Optimize cofactors: B6 as P5P, iron, and magnesium all support the serotonin synthesis pathway from tryptophan.
Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Low tryptophan with elevated hs-CRP is an inflammation problem, not a dietary problem. The inflammation is consuming your serotonin precursor faster than any supplement can replace it.
Plasma tryptophan interpreted alongside kynurenine pathway markers identifies whether low serotonin substrate is dietary or inflammation-driven, determining the treatment target. Schedule a consultation for a complete tryptophan and gut-brain axis evaluation.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.